Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Novus Detox Center Hails Missouri Lawsuit Against Opioid Manufacturers
  • USA - English


News provided by

JoTo PR

Oct 17, 2017, 08:00 ET

Share this article

Share toX

Share this article

Share toX

NEW PORT RICHEY, Fla. (PRWEB) October 17, 2017 -- Missouri Attorney General Josh Hawley recently filed a lawsuit against three major opioid manufacturers, accusing them of a “deliberate campaign of fraud”;(1) and he has subsequently expanded his investigation to include seven additional pharmaceutical companies.(2) Novus Detox Center, a preeminent Florida-based drug treatment provider, believes painkiller manufacturers should be held responsible for their role in the U.S. opioid crisis and hopes that Missouri and other states will find recourse through the law.

In 2015, Missouri’s age-adjusted rate of drug overdose deaths was 17.9, with overdoses claiming 1,066 lives statewide.(3) Last year, opioid overdoses alone—including prescription painkillers and heroin—led to 712 fatalities in the St. Louis metro area that spans Missouri and Illinois.(1) Hawley claims that opioid manufacturers have directly contributed to the current crisis by deceiving physicians and patients about the risks of the medications they make and market.

Missouri’s June 2017 lawsuit outlines evidence against Purdue Pharma, Endo Health Solutions and Janssen Pharmaceuticals, and is seeking “hundreds of millions of dollars” in damages against them.(1) In late August, Hawley expanded his investigation to include seven additional firms—Allergan, Depomed, Insys, Mallinckrodt, Mylan, Pfizer and Teva Pharmaceuticals—that he believes may have engaged in “deception, fraud, false promise, misrepresentation, unfair practices, and/or the concealment, suppression or omission of material facts in connection with the sale or advertisement of opioids.”(2)

“Opioid manufacturers have long downplayed or even falsified the risks of their prescription painkillers, spending vast sums on marketing, advertising and lobbying while leaving states to deal with rising opioid use disorders and overdose deaths,” asserted Bryn Wesch, CEO of Novus Detox Center. “If pharmaceutical firms had been transparent about opioids’ potential for misuse and abuse from the outset, we likely would not be dealing with a national epidemic today. Instead, their relentless pursuit of profits and callous disregard for patients’ long-term health and wellbeing continues to destroy lives and impose a growing economic burden.”

Missouri’s legal salvo follows similar cases initiated by Mississippi and Ohio earlier this year(1) as well as a Cherokee Nation opioid lawsuit filed in April. Though some policy experts suggest the allegations may be challenging to prove, oxycodone manufacturer Mallinckrodt has already agreed to pay a $35 million settlement following a U.S. Drug Enforcement Administration (DEA) investigation.(1) Among the evidence cited in Hawley’s lawsuit are drug makers’ dismissal of addiction symptoms as “pseudoaddiction,” Purdue’s “medically inaccurate” Opioid Risk Tool and pharmaceutical firms’ use of third-party advocacy groups to disseminate misleading narratives regarding opioids’ safety.(1)

“The sheer number of patients prescribed opioids—combined with the push for high-dose painkillers and their widespread use to treat chronic pain—has left millions of Americans trapped in a vicious cycle of dependency,” explained Wesch. “It’s vital to help those with substance use disorders obtain the treatment they need to safely taper down from and end their opioid use, and we believe painkiller manufacturers should be helping to fund those treatments. As a growing number of states pursue legal recourse to hold drug manufacturers accountable for their actions and deceptions, I hope we will see more patients gain access to the care they need to reclaim their lives from opioids.

Wesch advocates for patients to receive expert, integrated care throughout their journey to recovery, from safe and effective opioid detox programs to referrals to reputable drug rehab and outpatient services. She is a proponent of medically supervised and individually customized detox treatments coupled with emotional support to help recondition both body and mind, creating a solid foundation for sustainable sobriety and empowering patients to achieve a healthy, drug-free life.

For more information on Novus Detox Center and its medically supervised opioid treatment programs, visit https://novusdetox.com.

About Novus Detox Center:
Novus Detox Center is soon to be operating two inpatient medical detox facilities that are licensed by the Florida Department of Children and Families and have earned The Joint Commission’s Gold Seal of Approval for Behavioral Health Care Accreditation. Renowned for its pioneering approach to Sustainable Sobriety™, Novus provides safe and effective alcohol and drug detox programs that combine next-generation treatment protocols, 24/7 medical supervision and integrated, individualized care. By conditioning the body and mind to re-imagine a fulfilling, drug-free future, Novus empowers patients on their journey to recovery and creates a solid foundation for long-term success. Novus is committed to leading the way in patient experience, both as a detoxification expert and a supportive partner in ongoing health and wellness, and is dedicated to pushing industry standards forward. The original Florida detox facility is located in New Port Richey (outside Tampa) and another is soon to open in West Palm Beach; both feature a wide range of amenities, delicious and healthy meals, and a relaxing, spa-like environment to ensure the withdrawal process is as stress-free and comfortable and as possible. For more information on Novus’ medically supervised detox programs, visit https://novusdetox.com.
1. Bouscaren, Durrie. “Missouri Attorney General Sues Three Opioid Drugmakers Over False Claims, Advertising”; St. Louis Public Radio; June 21, 2017. news.stlpublicradio.org/post/missouri-attorney-general-sues-three-opioid-drugmakers-over-false-claims-advertising

2. Zhou, Janice. “Missouri Attorney General's Office Announces Investigation Into Opioid Marketing”; Columbia Missourian; August 30, 2017. columbiamissourian.com/news/state_news/missouri-attorney-general-s-office-announces-investigation-into-opioid-marketing/article_7f77aa2a-8dc7-11e7-bd4e-e30466f93dd6.html

3. Centers for Disease Control and Prevention (CDC). “Drug Overdose Death Data: 2015 Deaths”; CDC website; last updated December 16, 2016. cdc.gov/drugoverdose/data/statedeaths.html

Karla Jo Helms, JoTo PR, http://www.Jotopr.com, +1 888-202-4614 Ext: 802, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.